The US Court of Appeals for the Federal Circuit has upheld a patent covering Pfizer’s pain drug Lyrica, closing the market to any generic challengers until 2018.
Roche’s Indian subsidiary has sued Mylan and Bangalore-based pharmaceutical company Biocon at the Delhi High Court, for launching a biosimilar of its breast cancer drug Herceptin (trastuzumab).
Myriad Genetics has entered into a definitive agreement to acquire inflammatory and autoimmune diagnostics company Crescendo Bioscience for $270 million.
Law firm Baker & McKenzie has hired pharmaceutical lawyer Julian Thurston as a consultant in its global pharmaceutical and healthcare industry group.
UK IP law firm Powell Gilbert has appointed solicitor and medical doctor Tess Waldron as an associate.
A US medical research foundation has received about $131.2 million in damages after a jury found that two of its patents covering cochlear implants were infringed.
Healthcare company Covidien PLC has been told it did not infringe patents belonging to a Johnson & Johnson-owned company through using its ultrasonic dissection device.
On January 28, Teva announced that the FDA had approved its supplemental new drug application for a new formulation of its biggest selling drug Copaxone.
The UK High Court has decided to award Slovenian generic pharmaceutical company KRKA damages after a preliminary injunction enforced against the company by AstraZeneca was discharged.
Law firm Blank Rome LLP has expanded its IP litigation group with the appointment of Christopher Hu.